129 related articles for article (PubMed ID: 6967747)
1. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo.
Mitchell BS; Koller CA; Heyn R
Blood; 1980 Sep; 56(3):556-9. PubMed ID: 6967747
[TBL] [Abstract][Full Text] [Related]
2. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
3. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
4. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
5. Deoxyribonucleoside triphosphate accumulation by leukemic cells.
Mitchell BS; Edwards NL; Koller CA
Blood; 1983 Aug; 62(2):419-24. PubMed ID: 6603241
[TBL] [Abstract][Full Text] [Related]
6. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
Kefford RF; Fox RM
Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
[TBL] [Abstract][Full Text] [Related]
7. The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia.
Hallam LJ; Van der Weyden MB; Ackland SP; Bagnara AS; Whiteside MG
Scand J Haematol; 1984 Jan; 32(1):55-64. PubMed ID: 6607510
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in vitro.
Begleiter A; Pugh L; Israels LG; Johnston JB
Cancer Res; 1988 Jul; 48(14):3981-6. PubMed ID: 3260129
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
10. ATP depletion as a consequence of adenosine deaminase inhibition in man.
Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
[TBL] [Abstract][Full Text] [Related]
11. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.
Koller CA; Mitchell BS; Grever MR; Mejias E; Malspeis L; Metz EN
Cancer Treat Rep; 1979; 63(11-12):1949-52. PubMed ID: 316725
[No Abstract] [Full Text] [Related]
13. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
Bagnara AS; Hershfield MS
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
[TBL] [Abstract][Full Text] [Related]
14. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
15. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
16. S-adenosylhomocysteine hydrolase inactivation and purine toxicity in cultured human T- and B-lymphoblasts.
Young GJ; Hallam LJ; Jack I; Van Der Weyden MB
J Lab Clin Med; 1984 Jul; 104(1):86-95. PubMed ID: 6330251
[TBL] [Abstract][Full Text] [Related]
17. Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin.
Matsumoto SS; Yu AL; Yu J
Cancer Invest; 1985; 3(3):225-33. PubMed ID: 3873981
[TBL] [Abstract][Full Text] [Related]
18. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
19. Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.
Brox LW; Pollock E; Belch A
Cancer Chemother Pharmacol; 1982; 9(1):49-52. PubMed ID: 6982786
[TBL] [Abstract][Full Text] [Related]
20. Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin.
Russell NH; Prentice HG; Lee N; Piga A; Ganeshaguru K; Smyth JF; Hoffbrand AV
Br J Haematol; 1981 Sep; 49(1):1-9. PubMed ID: 6974003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
